CNS Lymphoma: CSF Biopsy Shows High Clinical Impact

A significant advancement in the diagnosis and management of central nervous system lymphoma (CNSL) is emerging, with new data demonstrating a clinically meaningful impact from cerebrospinal fluid (CSF) liquid biopsies in 82% of cases. Published in Lymphatics, the retrospective analysis of 50 CSF samples and 48 patients highlights the potential of tests like Summit™ and Vantage™ to provide actionable insights, particularly for patients where traditional tissue biopsies are challenging or impossible.

CNSL, a rare and aggressive form of cancer, presents unique diagnostic challenges. Traditional methods rely heavily on tissue biopsies, which aren’t always feasible due to tumor location or patient condition. The rise of liquid biopsies – analyzing circulating tumor DNA (ctDNA) in fluids like CSF – represents a paradigm shift in cancer diagnostics, offering a less invasive and potentially more comprehensive approach. This study builds on a growing body of evidence supporting the utility of CSF liquid biopsies in hematologic malignancies.

The Summit test, utilizing duplex next-generation sequencing and low-pass whole-genome sequencing, detected significant variants in 64% of samples, aligning with AMP/ASCO/CAP guidelines. Importantly, the study also validated the accuracy of negative results, confirming 50% of negative cases through clinical follow-up. The ability to track variant allele frequency (VAF) longitudinally, as highlighted by Dr. Michael Youssef, is particularly valuable for real-time monitoring of treatment response – a critical need in aggressive lymphomas.

The Forward Look

The findings from this study are likely to accelerate the adoption of CSF liquid biopsies in the clinical management of CNSL. However, several key developments will shape the future of this technology. First, the expanded capabilities of the updated Summit assay – now analyzing indels, copy-number variants, fusions, tumor mutational burden, and microsatellite instability – will provide an even more comprehensive genomic profile. This broader analysis will likely lead to the identification of novel therapeutic targets and personalized treatment strategies.

Second, we can anticipate increased integration of these liquid biopsy results into clinical trial design. Monitoring ctDNA dynamics during treatment could serve as a sensitive biomarker for early response assessment, potentially allowing for adaptive trial designs and faster evaluation of new therapies. Furthermore, the cost and accessibility of these tests will be crucial for widespread implementation. As technology advances and competition increases, we can expect to see a reduction in costs, making this valuable diagnostic tool available to a broader patient population. Finally, ongoing research will focus on refining the sensitivity and specificity of these assays, minimizing false negatives and ensuring accurate clinical interpretation. The field is rapidly evolving, and CSF liquid biopsies are poised to become an indispensable component of CNSL diagnosis and management.

References

1. Larson A, Udhane V, Adams JN, et al. Demonstrating the impact of the Belay cerebrospinal fluid liquid biopsy tests Summit™ and Vantage™ to inform diagnosis and management of central nervous system lymphoma. Lymphat. 2026;4(1):9. doi:10.3390/lymphatics4010009
2. Belay Diagnostics reports 82% clinical impact rate for Summit™ and Vantage™ in CNS lymphoma study. News release. Belay Diagnostics. March 24, 2026. Accessed March 26, 2026. https://tinyurl.com/y5ttcrmj